Clinical Trials Logo

Clinical Trial Summary

The investigators have developed a proprietary blend of amino acids that they think will help to prevent or reduce the severity of delirium in older people who are hospitalized for certain infections. In this study, up to 45 people will be enrolled. 15 will be asked to drink this blend twice a day for up to 4 days, and 15 will drink a placebo (sugar water) for the same time period. The other 15 subjects will be non-delirious control subjects who do not consume any study products.


Clinical Trial Description

This will be a controlled, randomized pilot study to determine the effectiveness of a specific amino acid supplement developed by the investigators versus standard treatment in mitigating delirium in geriatric patients at hospitalized UAMS for certain infections. Up to 30 delirious and 15 non-delirious subjects of any gender or ethnicity will be enrolled (45 subjects maximum). 15 will be asked to drink this blend twice a day for up to 4 days, and 15 will drink a placebo (sugar water) for the same time period. The other 15 subjects will be non-delirious control subjects who do not consume any study products. All subjects will undergo 2-5 blood draws and 3-7 cognitive assessments while they are admitted to the hospital, depending on study group assignment and discharge date. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05066503
Study type Interventional
Source University of Arkansas
Contact Gohar Azhar, M.D.
Phone 5015265935
Email azhargohar@uams.edu
Status Recruiting
Phase N/A
Start date November 16, 2020
Completion date March 2025